RMS13: Risk Adapted Focal Proton Beam Radiation and/or Surgery in Participants with Low and Intermediate Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy


Solid Tumor : Rhabdomyosarcoma (Low-risk and intermediate-risk)


The standard treatment for Rhabdomyosarcoma is a combination of chemotherapy (treatment with anti-cancer drugs), plus surgery and or radiation therapy (the use of high energy X-rays to kill cancer cells).

One goal of this study is to find the most effective treatment with the least amount of therapy that will still cure participants with low-risk Rhabdomyosarcoma.

There are three parts to this study:


Eligibility criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Matthew Krasin, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.